keyword
MENU ▼
Read by QxMD icon Read
search

III stage colon cancer

keyword
https://www.readbyqxmd.com/read/28717852/elevated-s100a8-protein-expression-in-breast-cancer-cells-and-breast-tumor-stroma-is-prognostic-of-poor-disease-outcome
#1
P Miller, K M Kidwell, D Thomas, M Sabel, J M Rae, D F Hayes, B I Hudson, D El-Ashry, M E Lippman
PURPOSE: Elevated S100A8 expression has been observed in cancers of the bladder, esophagus, colon, ovary, and breast. S100A8 is expressed by breast cancer cells as well as by infiltrating immune and myeloid cells. Here we investigate the association of elevated S100A8 protein expression in breast cancer cells and in breast tumor stroma with survival outcomes in a cohort of breast cancer patients. PATIENTS AND METHODS: Tissue microarrays (TMA) were constructed from breast cancer specimens from 417 patients with stage I-III breast cancer treated at the University of Michigan Comprehensive Cancer Center between 2004 and 2006...
July 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28714378/utilization-of-capecitabine-plus-oxaliplatin-and-5-fluorouracil-folinic-acid-plus-oxaliplatin-in-the-adjuvant-treatment-of-stage-iib-and-stage-iii-colon-cancer-a-multi-centre-retrospective-chart-review-study
#2
Aaron Sha, Shirin Abadi, Sharlene Gill
Purpose First, to assess drug utilization rates of capecitabine plus oxaliplatin (CAPOX) versus 5-fluorouracil plus oxaliplatin (mFOLFOX6) regimens in the treatment of stage IIB and stage III colon cancer. Second, to assess patient characteristics used to select CAPOX versus FOLFOX therapy, dose-limiting toxicities, dose intensities and treatment completion rates. Methods Patients with resected stage IIB or stage III colon cancer from five British Columbia Cancer Agency centres treated with CAPOX or mFOLFOX6 were selected for the analysis...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28710725/clinicopathologic-parameters-associated-with-postoperative-complications-and-risk-factors-for-tumor-recurrence-and-mortality-after-tumor-resection-of-patients-with-colorectal-cancer
#3
Z Bai, J Wang, T Wang, Y Li, X Zhao, G Wu, Y Yang, W Deng, Z Zhang
OBJECTIVE: To delineate the association of postoperative complications with clinicopathologic factors and to identify risk factors for tumor recurrence and mortality after tumor resection in patients with colorectal cancer (CRC). METHODS: The clinical data of 1144 patients with CRC who underwent surgical intervention between 2003 and 2013 were retrieved. Correlations of postoperative complications with clinicopathologic factors were examined using univariate analysis...
July 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28706889/long-term-oncologic-outcomes-of-laparoscopic-surgery-for-splenic-flexure-colon-cancer-are-comparable-to-conventional-open-surgery
#4
Min Ki Kim, In Kyu Lee, Won-Kyung Kang, Hyeon-Min Cho, Bong-Hyeon Kye, Heba Essam Jalloun, Jun-Gi Kim
PURPOSE: Few studies about laparoscopic surgery for splenic flexure colon cancer have been published. This study aims to compare the short- and long-term outcomes of laparoscopic surgery for splenic flexure colon cancer with those of conventional open surgery. METHODS: From January 2004 to December 2010, 51 consecutive patients who underwent curative resection for stages I-III splenic flexure colon cancer were enrolled. Thirty-three patients underwent laparoscopy-assisted colectomy, while 18 patients underwent conventional open colectomy...
July 2017: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/28687025/prognostic-value-of-positron-emission-tomography-computed-tomography-for-adjuvant-chemotherapy-of-colon-cancer
#5
HyungJoo Baik, Seok Mo Lee, Sang Hyuk Seo, Min Sung An, Kwang Hee Kim, Ki Beom Bae, Min Kyung Oh, Kwan Hee Hong
BACKGROUND: To assess the prognostic value of preoperative (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-risk stage II or stage III colon cancer who underwent FOLFOX chemotherapy. METHODS: The study included 166 patients with high-risk stage II or stage III colon cancer who received FOLFOX4 chemotherapy. Retrospective patient data were analysed including pathological stage, histology, disease-free survival (DFS) and the maximum standardized uptake value (SUVmax ) of the primary tumour on (18) F-fluorodeoxyglucose positron emission tomography/computed tomography...
July 7, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28669606/dose-response-effects-of-aerobic-exercise-among-colon-cancer-survivors-a-randomized-phase-ii-trial
#6
Justin C Brown, Andrea B Troxel, Bonnie Ky, Nevena Damjanov, Babette S Zemel, Michael R Rickels, Andrew D Rhim, Anil K Rustgi, Kerry S Courneya, Kathryn H Schmitz
BACKGROUND: Observational studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. However, the feasibility and safety of prescribing higher volumes of physical activity to survivors of colon cancer are unknown. Furthermore, the pathways through which exercise may reduce disease recurrence are unknown. PATIENTS AND METHODS: Survivors of stage I to III colon cancer were randomized to usual-care control, 150 minutes per week of aerobic exercise (low-dose), or 300 minutes per week of aerobic exercise (high-dose)...
June 17, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28651158/prospective-validation-of-a-lymphocyte-infiltration-prognostic-test-in-stage-iii-colon-cancer-patients-treated-with-adjuvant-folfox
#7
Jean-François Emile, Catherine Julié, Karine Le Malicot, Come Lepage, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean-Luc Van Laethem, Stéphanie Dimet, Camille Boulagnon-Rombi, Marc-Antoine Allard, Frédérique Penault-Llorca, Jaafar Bennouna, Pierre Laurent-Puig, Julien Taieb
BACKGROUND: The prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use. PATIENTS AND METHODS: According to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study...
June 23, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28637568/disparities-in-the-age-related-rates-of-colorectal-cancer-in-the-united-states
#8
Emmanuel Gabriel, Katherine Ostapoff, Kristopher Attwood, Eisar Al-Sukhni, Patrick Boland, Steven Nurkin
The incidence of colorectal cancer (CRC) among Americans under the age of 50 years is increasing. The purpose of this study was to identify racial and socioeconomic disparities associated with this trend. The National Cancer Data Base was used to identify patients with CRC from 1998 to 2011. Patients were stratified by age (<50 versus >60 years), with ages 50 to 60 years omitted from the analysis to minimize overlapping trends between the two age groups. Relative frequencies (RFs) by year were plotted against demographic variables...
June 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28634730/phase-iii-trial-comparing-uft%C3%A2-%C3%A2-psk-to-uft%C3%A2-%C3%A2-lv-in-stage-iib-iii-colorectal-cancer-mcsgo-cctg
#9
Yasuhiro Miyake, Junichi Nishimura, Takeshi Kato, Masataka Ikeda, Masaki Tsujie, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Hirofumi Yamamoto, Mitsugu Sekimoto, Riichiro Nezu, Yuichiro Doki, Masaki Mori
PURPOSE: Oral adjuvant uracil and tegafur plus leucovorin (UFT/LV) is not inferior to standard weekly fluorouracil and folinate for stage II/III colon cancer. However, protein-bound polysaccharide K (PSK) has been evaluated as postoperative adjuvant therapy for colorectal cancer. This report is the first of MCSGO-CCTG, which compared UFT/LV to UFT/PSK as adjuvant chemotherapy for stage IIB or III colorectal cancer in patients who had undergone Japanese D2/D3 lymph node dissection. METHODS: The primary endpoint was the 3-year disease-free survival (DFS)...
June 20, 2017: Surgery Today
https://www.readbyqxmd.com/read/28624221/mir-1290-is-a-biomarker-in-dna-mismatch-repair-deficient-colon-cancer-and-promotes-resistance-to-5-fluorouracil-by-directly-targeting-hmsh2
#10
Ling Ye, Tao Jiang, Huanzhang Shao, Lin Zhong, Zhaowen Wang, Yuan Liu, Huamei Tang, Bingyu Qin, Xiaoqing Zhang, Junwei Fan
5-Fluorouracil (5FU)-based adjuvant therapy is the first-line therapy for treating stage II and III colon cancer after surgery. However, its therapeutic efficacy is limited because of chemoresistance, especially in deficient mismatch repair (dMMR) colon cancer. Here, we first used laser capture microdissection to obtain purified cells from four dMMR and four proficient mismatch repair (pMMR) colon cancer tissues. Second, microRNA (miRNA) microarray chips were used to identify miRNAs that are differentially expressed between these two classes of tumors...
June 16, 2017: Molecular Therapy. Nucleic Acids
https://www.readbyqxmd.com/read/28622612/influence-of-age-and-comorbidity-on-prognosis-and-application-of-adjuvant-chemotherapy-in-elderly-japanese-patients-with-colorectal-cancer-a-retrospective-multicentre-study
#11
Tomoki Yamano, Shinichi Yamauchi, Kei Kimura, Akihito Babaya, Michiko Hamanaka, Masayoshi Kobayashi, Miki Fukumoto, Kiyoshi Tsukamoto, Masafumi Noda, Naohiro Tomita, Kenichi Sugihara
BACKGROUND: Adjuvant therapy for colorectal cancer (CRC) in patients aged ≥75 years is supported by inadequate evidence, although such patients are increasing in number worldwide. PATIENTS AND METHODS: We assessed the influence of age and comorbidities on the prognosis of CRC in elderly patients using pooled data by the Japanese Study Group for Postoperative Follow-up of Colorectal Cancer. In total, 4598 patients (3304 with colon cancer and 1294 with rectal cancer) who underwent curative surgery from 2004 to 2006 were analysed with respect to age, Charlson comorbidity score (CS), tumour marker positivity, adjuvant therapy and prognosis...
August 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28617898/mutation-in-braf-v600e-a-poor-prognostic-marker-in-stage-iii-colon-cancers-with-deficient-mmr
#12
Sheik Emambux, Guillaume Mouillet, David Tougeron
No abstract text is available yet for this article.
June 15, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28608229/erratum-to-preplanned-safety-analysis-of-the-jfmc37-0801-trial-a-randomized-phase-iii-study-of-six-months-versus-twelve-months-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer
#13
Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko, Ken Kondo, Hideyuki Ishida, Genichi Nishimura, Kazuaki Sasaki, Takayuki Morita, Shoichi Hazama, Koutarou Maeda, Hideyuki Mishima, Hideyuki Ike, Sotaro Sadahiro, Kenichi Sugihara, Masazumi Okajima, Shigetoyo Saji, Junichi Sakamoto, Naohiro Tomita
No abstract text is available yet for this article.
June 12, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28601656/prognostic-relevance-of-src-activation-in-stage-ii-iii-colon-cancer
#14
Julia Martinez Perez, Iker Lopez-Calderero, Carmen Saez, Marta Benavent, Maria L Limon, Reyes Gonzalez-Exposito, B Soldevilla, Maria C Riesco-Martinez, Javier Salamanca, Amancio Carnero, Rocio Garcia-Carbonero
Src belongs to a family of cytoplasmic tyrosine kinases that play a key role in tumor initiation and progression. Src activation has been associated with a more aggressive neoplastic phenotype and induces resistance to platinum agents in preclinical models. The aim of our study was to assess the prognostic and/or predictive value of Src activation in stage II-III colon cancer patients. pSrc expression was assessed in paraffin-embedded tumor samples by immunohistochemistry (phospho Y418, ab4816, Abcam). Cases were classified by staining intensity in four categories: no staining (0), weak (1+), moderate (2+) and intense (3+) staining...
June 7, 2017: Human Pathology
https://www.readbyqxmd.com/read/28594974/association-between-prognosis-and-tumor-laterality-in-early-stage-colon-cancer
#15
Safiya Karim, Kelly Brennan, Sulaiman Nanji, Scott R Berry, Christopher M Booth
Importance: Recent data have suggested that disease biology and outcome of colon cancer may differ between right-sided and left-sided tumors. However, the literature on the prognostic value of tumor laterality is conflicting. Objective: To explore differences in laterality based on disease characteristics and outcomes in a population-based cohort of early-stage colon cancer. Design, Setting, and Participants: This investigation was a population-based retrospective cohort study of patients with early-stage colon cancer from the province of Ontario, Canada...
June 8, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28593861/challenges-behind-proving-efficacy-of-adjuvant-chemotherapy-after-preoperative-chemoradiation-for-rectal-cancer
#16
REVIEW
Carlos Carvalho, Rob Glynne-Jones
For patients with high-risk stage II or stage III colon cancer, adjuvant chemotherapy with fluoropyrimidine monotherapy reduces the risk of recurrence and death by approximately 20-30%. Additional improvements have been reported in three phase 3 colon cancer trials when oxaliplatin was added to the chemoradiation regimen, although the effect was mainly on disease-free survival. However, patients with rectal cancer were specifically excluded from these landmark studies because of potential toxicity and the confounding impact of radiotherapy and chemoradiation...
June 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28593306/comparative-analysis-of-tumor-cell-dissemination-to-the-sentinel-lymph-nodes-and-to-the-bone-marrow-in-patients-with-nonmetastasized-colon-cancer-a-prospective-multicenter-study
#17
Benjamin Weixler, Carsten T Viehl, Rene Warschkow, Ulrich Guller, Michaela Ramser, Guido Sauter, Markus Zuber
Importance: Small nodal tumor infiltrates (SNTI; isolated tumor cells and micrometastases) in sentinel lymph nodes and bone marrow micrometastases (BMM) were independently described as prognostic factors in patients with colon cancer. Objective: To examine the association between the occurrence of SNTI and BMM as well as their prognostic relevance. Design, Setting, and Participants: This prospective study was conducted at 3 university-affiliated institutions in Switzerland between May 2000 and December 2006...
June 7, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/28589428/annual-hazard-rate-of-relapse-of-stage-ii-and-iii-colorectal-cancer-after-primary-therapy
#18
N Mejri, M Dridi, S Labidi, H El Benna, N Daoud, H Boussen
PURPOSE: To report the annual hazard of relapse in stages II and III colorectal cancer (CRC) Tunisian patients treated with curative intent. We also aim to evaluate impact of oxaliplatine according to anatomo-clinical features. METHODS: We collected data about clinico-pathological parameters of 331 CRCs. We analyzed annual hazard of recurrence (locoregional and/or distant) of the overall population and several subgroups: colon cancer vs rectal cancer and stage II vs stage III...
June 6, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28576136/novel-apc-gene-mutations-associated-with-protein-alteration-in-diffuse-type-gastric-cancer
#19
Souvik Ghatak, Payel Chakraborty, Sandeep Roy Sarkar, Biswajit Chowdhury, Arup Bhaumik, Nachimuthu Senthil Kumar
BACKGROUND: The role of adenomatous polyposis coli (APC) gene in mitosis might be critical for regulation of genomic stability and chromosome segregation. APC gene mutations have been associated to have a role in colon cancer and since gastric and colon tumors share some common genetic lesions, it is relevant to investigate the role of APC tumor suppressor gene in gastric cancer. METHODS: We investigated for somatic mutations in the Exons 14 and 15 of APC gene from 40 diffuse type gastric cancersamples...
June 2, 2017: BMC Medical Genetics
https://www.readbyqxmd.com/read/28561714/personalizing-adjuvant-therapy-for-stage-ii-iii-colorectal-cancer
#20
Nadine Jackson McCleary, Al B Benson, Rodrigo Dienstmann
This review focuses on three areas of interest with respect to the treatment of stage II and III colon and rectal cancer, including (1) tailoring adjuvant therapy for the geriatric population, (2) the controversy as to the optimal adjuvant therapy strategy for patients with locoregional rectal cancer and for patients with colorectal resectable metastatic disease, and (3) discussion of the microenvironment, molecular profiling, and the future of adjuvant therapy. It has become evident that age is the strongest predictive factor for receipt of adjuvant chemotherapy, duration of treatment, and risk of treatment-related toxicity...
2017: American Society of Clinical Oncology Educational Book
keyword
keyword
59219
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"